Nuke-- Your #2 is just what I was thinking. It makes so much more sense to repeat the positive Avid cash flow story and 10Q results BEFORE rather than after the Duke Haynes publication. After the Nature Med article lots of new people all over the world will be considering an investment in PPHM, and the Company's solvency will be part of their decision.
Plus the full CC transcript and voice recording talking about the Ph II cancer trials will also be available to new investors when the Nature article is published. People will go to the CC recording to learn about a new anti-viral company and discover they have landed on a state-of-the-art cancer company as well.
Everyone likes to hear a recent update from the management team before they buy, especially if you are a first time buyer.
News 
Market Data 
Discover 
